{
    "nct_id": "NCT05764954",
    "official_title": "A Prospective Clinical Trial of Tumor Immunomodulation Using Tumor-Treating Fields (TTFields) in Patients With Early-Stage Resectable Lung Adenocarcinoma",
    "inclusion_criteria": "* The participant (or legally acceptable representative [LAR], if applicable) provides written informed consent for the study.\n* The participant is â‰¥22 years of age on the day of signing informed consent.\n* The participant has clinical stage 1A2, 1A3 or IB biopsy-proven lung ADC and is eligible for anatomical resection.\n* The participant has a lung nodule >1 cm and suspected lung ADC with a plan to undergo biopsy.\n* The participant with multiple nodules has one nodule that meets the criteria.\n* The participant has no history of prior malignancy in the chest or has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.\nHealthy volunteers allowed\nMust have minimum age of 22 Years",
    "exclusion_criteria": "* Patients receiving therapy for concurrent active malignancy\n* Patients with a history of cardiac arrhythmias and/or pacemaker use\n* Patients with lung nodules <1cm\n* Patients with lung nodules that are pure ground glass opacities (GGOs) of any size\n* Patients with lung nodules that are <50% solid of any size",
    "miscellaneous_criteria": ""
}